Related Experiment Video
Updated: Jul 10, 2026
07:21
Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
Published on: September 28, 2015
Urotensin II and atherosclerosis
Gervaise Loirand1, Malvyne Rolli-Derkinderen, Pierre Pacaud
1Inserm U533, Nantes F-44000, France.
Peptides
|October 16, 2007
Summary
Urotensin II (U-II) and its receptor (UT) may play a role in atherosclerosis. Elevated U-II levels and receptor expression in human coronary arteries suggest involvement in disease initiation and progression.
Area of Science:
- Cardiovascular Biology
- Endocrinology
- Molecular Medicine
Background:
- Urotensin II (U-II) is a potent vasoactive peptide acting via the UT receptor.
- Elevated plasma U-II levels are observed in patients with atherosclerosis and coronary artery disease.
- U-II and UT receptor are expressed in human atherosclerotic coronary arteries.
Purpose of the Study:
- To investigate the potential role of Urotensin II and its receptor in atherosclerosis.
- To explore the cellular expression and functional effects of U-II/UT in the context of cardiovascular disease.
Main Methods:
- Analysis of U-II and UT receptor expression in human atherosclerotic coronary arteries.
- Investigation of UT receptor regulation by inflammatory stimuli.
- Assessment of U-II-mediated effects on endothelial cells, smooth muscle cells, and monocyte chemotaxis.
Main Results:
- U-II is expressed in endothelial cells, smooth muscle cells, and macrophages within atherosclerotic lesions.
- UT receptor expression is increased by inflammatory stimuli.
- U-II activation of UT receptor promotes endothelial and smooth muscle cell proliferation and monocyte migration.
Conclusions:
- Urotensin II and its UT receptor are implicated in the pathogenesis of atherosclerosis.
- Beyond its vasoactive properties, U-II signaling may contribute to atherosclerotic plaque development and progression.
- Targeting the U-II/UT pathway could offer novel therapeutic strategies for atherosclerosis.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:29Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...